Who are Complix's investors?

Complix's investors include Andera Partners, Vesalius Biocapital Partners.

Complix

2 known investors

Complix develops Cell Penetrating Alphabodies, a protein-based therapeutic platform designed to target intracellular disease targets that are inaccessible to conventional antibodies and small molecule drugs. The company is building a pipeline of therapeutics primarily focused on cancer, autoimmunity, and viral diseases.

Biotech

Investors · 2

Andera PartnersParis

Vesalius Biocapital PartnersLuxembourg · $11M

Competitors · 1

by search overlap

Exelixis3 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

Companies competing with Complix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Complix do?: Complix develops Cell Penetrating Alphabodies, a protein-based therapeutic platform designed to target intracellular disease targets that are inaccessible to conventional antibodies and small molecule drugs. The company is building a pipeline of therapeutics primarily focused on cancer, autoimmunity, and viral diseases.
Who are Complix's investors?: Complix's investors include Andera Partners, Vesalius Biocapital Partners.